Ibio Inc Stock News

These penny stocks are companies that have a crucial year ahead in terms of industry turnaround or company specific product development. The post 7 Penny Stocks In a Make-or-Break Year appeared first

With iBio making key executive-level appointments and recording excellent fiscal stats, IBIO stock's value proposition is hard to ignore. The post Hold iBio Shares as Q2 Highlights Strong Product Cata

iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccine

iBio, Inc. (IBIO) CEO Tom Isett on Q2 2021 Results - Earnings Call Transcript

BRYAN, Tx., Feb. 16, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its fina

In the midst of an expensive market, traders are turning to penny stocks as a cheaper alternative. But avoid these seven risky penny names.

BRYAN, Texas, Feb. 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that i

If January is a sign of things to come for 2021, traders and investors are going to make a lot of money this year. 4 penny stocks on the move are Anavex Life Sciences (NASDAQ: AVXL), iBio Inc (NYSEMKT

We may be seeing some sector rotation, and many companies that have made big moves in recent weeks have stocks under $10. The post 7 Stocks Under $10 to Buy for February  appeared first on InvestorPl

The stock price of IBIO Inc (NYSEAMERICAN: IBIO) increased by 20.55%. This is why it happened.

One analyst says investors are underappreciating the biotech's growth prospects.

Shares of IBIO stock are taking off on Friday after an analyst from Cantor Fitzgerald initiated an Overweight rating and $3 price target. The post IBIO Stock Alert: Analyst Call Sends Shares of Pharma

Phase 3 trial delays are pushing NVAX stock down, but the biotech still has a reliable vaccine candidate expected to generate $3.9 billion. The post NVAX Stock Is Worth a Small Position but Vaccine Ra

Innovation paid off big for investors.

BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the ap